Literature DB >> 12539555

Clinical significance and assessment of cytokines in various stages of ulcerative colitis.

K Zou1, S Liu, X Xie, C Yi.   

Abstract

In order to study the clinical significance and change of interleukin (IL)-1 beta and IL-10 concentration in intestinal mucosal tissues in various stage of ulcerative colitis (UC), IL-1 beta and IL10 levels were measured by enzyme linked immunosorbent assays (ELISA). Our results showed that IL-beta level caused by spontaneous secretion in the intestinal mucous tissues in active stage of ulcerative colitis was significantly higher than that in normal controls and in remission stage of ulcerative colitis (P < 0.01, P < 0.001). IL-10 level in various stage of UC was relatively lower in controls, but there was no significantly difference between the two groups. Our study suggested that higher IL-1 beta level in active might play an important role in pathogenesis of UC, and IL-10, as an anti-inflammatory cytokine, was low in active UC, suggesting that it may be a important factor contributing to the development of higher IL-1 beta level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12539555     DOI: 10.1007/BF02886564

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  7 in total

1.  Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells.

Authors:  S A Strong; T T Pizarro; J S Klein; F Cominelli; C Fiocchi
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

2.  Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.

Authors:  Y R Mahida; K Wu; D P Jewell
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

3.  Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation.

Authors:  S Nikolaus; J Bauditz; P Gionchetti; C Witt; H Lochs; S Schreiber
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

4.  Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; H G Thiele; A Raedler
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

5.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

Authors:  D F Fiorentino; A Zlotnik; P Vieira; T R Mosmann; M Howard; K W Moore; A O'Garra
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

6.  Involvement of interleukin-4 and -10 in inflammatory bowel disease.

Authors:  O H Nielsen; T Køppen; N Rüdiger; T Horn; J Eriksen; I Kirman
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

7.  Subtherapeutic corticosteroids potentiate the ability of interleukin 10 to prevent chronic inflammation in rats.

Authors:  H H Herfarth; U Böcker; R Janardhanam; R B Sartor
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682

  7 in total
  1 in total

Review 1.  Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.

Authors:  Hui Peng; Wei Wang; Mo Zhou; Rui Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2013-05-25       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.